Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, Fremont DH, Diamond MS.

Cell Host Microbe. 2007 Apr 19;1(2):135-45.

3.

Perturbation of B cell activation in SLAM-associated protein-deficient mice is associated with changes in gammaherpesvirus latency reservoirs.

Kim IJ, Burkum CE, Cookenham T, Schwartzberg PL, Woodland DL, Blackman MA.

J Immunol. 2007 Feb 1;178(3):1692-701. Erratum in: J Immunol. 2007 Jun 1;178(11):7487.

4.

The neutralizing antibody response against West Nile virus in naturally infected horses.

Sánchez MD, Pierson TC, Degrace MM, Mattei LM, Hanna SL, Del Piero F, Doms RW.

Virology. 2007 Mar 15;359(2):336-48. Epub 2006 Oct 20.

5.

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Morrey JD, Siddharthan V, Olsen AL, Roper GY, Wang H, Baldwin TJ, Koenig S, Johnson S, Nordstrom JL, Diamond MS.

J Infect Dis. 2006 Nov 1;194(9):1300-8. Epub 2006 Sep 22.

PMID:
17041857
6.

Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.

Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi BE, Olshevsky U, Fremont DH, Pierson TC, Diamond MS.

J Virol. 2006 Dec;80(24):12149-59. Epub 2006 Oct 11.

7.

Preparation and immunogenic properties of a recombinant West Nile subunit vaccine.

Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa A, Humphreys T, Weeks-Levy C.

Vaccine. 2007 Jan 5;25(3):414-23. Epub 2006 Aug 30.

8.

Crystal structure of the West Nile virus envelope glycoprotein.

Nybakken GE, Nelson CA, Chen BR, Diamond MS, Fremont DH.

J Virol. 2006 Dec;80(23):11467-74. Epub 2006 Sep 20.

9.

Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites.

Stiasny K, Kiermayr S, Holzmann H, Heinz FX.

J Virol. 2006 Oct;80(19):9557-68.

10.

Baboon model for West Nile virus infection and vaccine evaluation.

Wolf RF, Papin JF, Hines-Boykin R, Chavez-Suarez M, White GL, Sakalian M, Dittmer DP.

Virology. 2006 Nov 10;355(1):44-51. Epub 2006 Aug 10.

11.

Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus.

Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, Kramer RA, Clijsters-van der Horst M, de Jong M, Jongeneelen M, Thijsse S, Smit R, Visser TJ, Bijl N, Marissen WE, Loeb M, Kelvin DJ, Preiser W, ter Meulen J, de Kruif J.

J Virol. 2006 Jul;80(14):6982-92.

12.

A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus.

Zhang S, Li L, Woodson SE, Huang CY, Kinney RM, Barrett AD, Beasley DW.

Virology. 2006 Sep 15;353(1):35-40. Epub 2006 Jun 27.

13.

Production and characterization of vaccines based on flaviviruses defective in replication.

Mason PW, Shustov AV, Frolov I.

Virology. 2006 Aug 1;351(2):432-43. Epub 2006 May 18.

14.

Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Mehlhop E, Diamond MS.

J Exp Med. 2006 May 15;203(5):1371-81. Epub 2006 May 1.

15.

A live, attenuated recombinant West Nile virus vaccine.

Monath TP, Liu J, Kanesa-Thasan N, Myers GA, Nichols R, Deary A, McCarthy K, Johnson C, Ermak T, Shin S, Arroyo J, Guirakhoo F, Kennedy JS, Ennis FA, Green S, Bedford P.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9. Epub 2006 Apr 14. Erratum in: Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10823.

16.

A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Pierson TC, Sánchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW.

Virology. 2006 Mar 1;346(1):53-65. Epub 2005 Dec 2.

17.
18.

Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus.

Gould LH, Sui J, Foellmer H, Oliphant T, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, de Silva AM, Diamond MS, Koski RA, Marasco WA, Fikrig E.

J Virol. 2005 Dec;79(23):14606-13.

19.

Structural basis of West Nile virus neutralization by a therapeutic antibody.

Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH.

Nature. 2005 Sep 29;437(7059):764-9.

PMID:
16193056
20.

Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains.

Beasley DW, Whiteman MC, Zhang S, Huang CY, Schneider BS, Smith DR, Gromowski GD, Higgs S, Kinney RM, Barrett AD.

J Virol. 2005 Jul;79(13):8339-47.

Supplemental Content

Support Center